Butterfly Network (BFLY) Q4 2022: Software and Services Jump 38% as Recurring Revenue Model Gains Traction
Butterfly Network’s Q4 marked a strategic pivot toward enterprise software and recurring services, with software and services revenue surging and comprising a third of total revenue. The company’s shift away from lower-margin e-commerce and focus on hospital systems and global deployments is reshaping its revenue mix and operating discipline. Guidance for 2023 hinges on expanding Blueprint software adoption, international partnerships, and cost discipline, as Butterfly seeks to capitalize on its chip-based platform advantage amid macro and hospital resource constraints.
Summary
- Enterprise Software Penetration: Butterfly’s Blueprint platform is unlocking health system deployments and recurring revenue streams.
- Revenue Mix Transformation: Software and services now comprise a significantly larger share, supporting margin expansion.
- Execution Focus Intensifies: Cost discipline and targeted commercial restructuring are designed to extend cash runway and accelerate scale in core markets.
Business Overview
Butterfly Network is a medical technology company pioneering handheld, chip-based ultrasound devices paired with artificial intelligence (AI) and enterprise software. Its core business spans hardware sales (Butterfly IQ Plus), subscription-based software and services (Blueprint), and global health and veterinary segments. The company generates revenue through device sales, recurring software subscriptions, and services, targeting hospitals, medical schools, global health initiatives, and veterinary practices.
Performance Analysis
Q4 2022 results reflect a deliberate shift in Butterfly’s business model, with software and services revenue climbing nearly 38% year-over-year and now accounting for 33% of total revenue, up 9 percentage points from the prior year. This expansion is underpinned by a growing installed base, increased software renewals, and more institutions opting for software-only deployments—a notable validation of the Blueprint platform’s value proposition.
Product revenue declined 12% versus Q4 2021, driven by lower health system and e-commerce volumes, partly the result of macro pressures and a strategic de-emphasis on individual device sales. However, higher average selling prices and global health deployments partially offset these declines, while adjusted gross margin rose to 54% from 40% last year, reflecting a richer mix of subscription revenue and improved manufacturing productivity.
- Recurring Revenue Momentum: Software and services growth signals a stickier, higher-margin model taking hold.
- Margin Expansion: Gross margin improvement is tied directly to software mix and ASP gains rather than volume recovery.
- Cash Burn Reduction: Monthly cash use dropped to $10 million from over $18 million, driven by targeted cost reductions across R&D, sales, and G&A.
Despite top-line growth and margin gains, Butterfly remains unprofitable, with a Q4 adjusted EBITDA loss of $29.3 million. The company’s disciplined cost actions and restructuring are designed to extend its cash runway and support investment in high-ROI initiatives, especially as it navigates elongated hospital sales cycles and macro headwinds.
Executive Commentary
"Butterfly is the only handheld whole body ultrasound scanner. Paired with leading edge AI, we empower healthcare professionals to make better clinical decisions... Having started an industry by putting DNA sequencing on a chip, I can confidently say that Butterfly has forked history and that ultrasound on a chip and AI will become as ubiquitous as a stethoscope."
Dr. Jonathan Rothberg, Founder and Interim Chief Executive Officer
"Our plan will allow us to navigate the headwinds from the macro environment while still realizing the vision and mission of Butterfly and to capitalize on this attractive market opportunity. We have a solid cash position and we will continue to invest in our current and future growth while closely scrutinizing our investments to ensure that we pick the maximum ROI projects and carefully evaluate trade-offs."
Heather Goetz, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Enterprise Software as a Trojan Horse
Butterfly’s Blueprint, enterprise ultrasound software, is increasingly deployed as a software-only solution, allowing the company to enter large health systems and lay the groundwork for future device sales. This “Trojan horse” strategy is proving effective, as software deployments precede broader hardware adoption and recurring revenue opportunities across departments.
2. Recurring Revenue and Margin Focus
The mix shift toward software and services is structurally expanding margins and reducing reliance on volatile device sales. As more institutions subscribe to Blueprint and renew software, Butterfly’s revenue base becomes stickier, more predictable, and higher margin—key for long-term sustainability.
3. Global and Vertical Expansion
International partnerships, such as the Gates Foundation deployment in Kenya and distribution agreements in the UAE, India, and South Africa, are opening new addressable markets and validating the platform’s scalability. The veterinary business, now featured in major educational and commercial partnerships, is also emerging as a growth lever.
4. Cost Discipline and Cash Runway
Butterfly has implemented two rounds of cost reductions, cutting annual cash outlay by approximately $60 million and extending its cash runway into 2025. R&D, sales, and external spend have all been trimmed, with a focus on higher talent density and ROI-driven project selection.
5. Innovation Pipeline and Home Use Vision
Butterfly’s chip-based architecture enables rapid iteration and AI-driven image quality improvements, supporting a path toward home use and chronic disease management. Regulatory engagement and feasibility studies, such as the John Muir CHF study, are advancing the company’s North Star of democratizing imaging access beyond clinical settings.
Key Considerations
This quarter marks a turning point as Butterfly’s recurring revenue model and enterprise-first strategy become more central to its identity and growth prospects. Investors should weigh the following:
- Blueprint Platform’s Stickiness: Software-only deployments are giving Butterfly a scalable entry point into large health systems, with proven expansion potential into hardware and services as user adoption grows.
- Hospital Resource Constraints: Elongated sales cycles and delayed implementations are tied to post-COVID hospital staffing shortages, which management expects to gradually ease in 2023.
- Cost Structure Reset: Significant operating expense reductions are designed to preserve cash while maintaining innovation and commercial momentum in core markets.
- International and Vertical Diversification: Early success in global health and veterinary markets demonstrates the platform’s versatility but will require continued investment and execution to drive material revenue contributions.
Risks
Butterfly faces execution risk in scaling its enterprise and recurring revenue model, especially with hospital customers still constrained by labor and capital availability. Regulatory hurdles for home use, competitive responses from entrenched ultrasound players, and the need to prove sustained adoption beyond initial deployments are all nontrivial. Additionally, the company’s persistent operating losses and dependence on cash reserves heighten sensitivity to any delays in revenue ramp or margin expansion.
Forward Outlook
For Q1 2023, Butterfly guided to:
- Flat to slightly higher revenue versus Q1 2022, reflecting ongoing macro and hospital resource pressures.
For full-year 2023, management expects:
- Revenue growth in the high teens to low 20s percent range, with a stronger second half as hospital constraints ease and distribution partnerships ramp.
- Full-year adjusted EBITDA loss in the range of $85 to $95 million, reflecting continued cost discipline and phased savings realization.
Management emphasized that Blueprint momentum, expanded distribution, and operational focus are expected to drive sequential improvement, while cost reductions will extend the cash runway into 2025.
- Hospital sales cycles remain elongated but are expected to improve as the year progresses.
- Second half revenue ramp is contingent on macro recovery and commercial execution.
Takeaways
Butterfly’s Q4 results underscore a business in transition, as software and services become the engine of growth and margin expansion. The company’s disciplined pivot to enterprise deployments and recurring revenue, backed by cost control, is designed to weather macro uncertainty and position Butterfly for scalable, high-margin growth.
- Recurring Revenue Shift: The growing share of software and services is structurally improving margins and revenue visibility, but the company must now prove durable adoption and expansion within health systems.
- Execution on Enterprise and Global Strategy: Success in large accounts and new markets is critical to justifying the company’s valuation and long-term vision.
- Watch for Commercial Traction and Cash Burn: Investors should closely monitor Blueprint expansion, hardware attach rates, and the pace of cash consumption as Butterfly navigates a resource-constrained environment.
Conclusion
Butterfly Network’s Q4 reflects disciplined execution and a clear pivot toward enterprise software and recurring revenue, with margin expansion and cost control supporting a longer cash runway. The path forward depends on converting Blueprint deployments into scaled device and service adoption, while maintaining innovation leadership in a competitive and evolving market.
Industry Read-Through
Butterfly’s results and strategy offer several industry signals: The shift toward software-driven, recurring revenue models is accelerating in medical device markets, with enterprise platforms serving as critical beachheads for broader hardware and service adoption. Hospital resource constraints remain a sector-wide headwind, but companies that can deliver rapid, scalable deployments and demonstrate clear ROI for health systems are likely to gain share. Butterfly’s chip-based, AI-enabled approach also underscores the disruptive potential of programmable hardware in imaging, with implications for both incumbent OEMs and digital health challengers seeking to democratize access and drive adoption beyond traditional clinical environments.